Amicogen Past Earnings Performance
Past criteria checks 0/6
Amicogen's earnings have been declining at an average annual rate of -49.7%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 10.7% per year.
Key information
-49.7%
Earnings growth rate
-49.5%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | 10.7% |
Return on equity | -9.4% |
Net Margin | -14.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%
Mar 21With EPS Growth And More, Amicogen (KOSDAQ:092040) Is Interesting
Mar 23Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?
Mar 05Is Amicogen (KOSDAQ:092040) A Risky Investment?
Feb 15What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?
Jan 31Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?
Jan 14Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?
Dec 30Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?
Dec 15Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?
Nov 30Revenue & Expenses BreakdownBeta
How Amicogen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 159,904 | -23,289 | 34,799 | 13,783 |
30 Sep 23 | 164,246 | -29,420 | 34,038 | 14,519 |
30 Jun 23 | 160,012 | -28,646 | 34,256 | 14,041 |
31 Mar 23 | 152,966 | -36,636 | 33,299 | 13,678 |
31 Dec 22 | 144,296 | -47,220 | 33,596 | 12,436 |
30 Sep 22 | 139,504 | -39,813 | 34,258 | 11,641 |
30 Jun 22 | 124,834 | -61,072 | 33,196 | 11,859 |
31 Mar 22 | 123,766 | -3,132 | 33,896 | 11,549 |
31 Dec 21 | 124,881 | 3,733 | 33,790 | 10,843 |
30 Sep 21 | 117,317 | 33,202 | 32,508 | 9,729 |
30 Jun 21 | 122,414 | 61,569 | 32,005 | 8,111 |
31 Mar 21 | 121,274 | 39,193 | 31,341 | 6,756 |
31 Dec 20 | 115,856 | 31,604 | 31,138 | 6,282 |
30 Sep 20 | 129,171 | 33,394 | 43,820 | 5,026 |
30 Jun 20 | 120,536 | 14,272 | 43,168 | 5,132 |
31 Mar 20 | 114,651 | -34,074 | 43,838 | 5,487 |
31 Dec 19 | 115,181 | 87 | 41,821 | 5,376 |
30 Sep 19 | 90,882 | 9,728 | 25,682 | 5,524 |
30 Jun 19 | 94,620 | 21,428 | 24,667 | 5,244 |
31 Mar 19 | 91,338 | 63,867 | 21,582 | 5,245 |
31 Dec 18 | 94,522 | 40,168 | 20,312 | 5,183 |
30 Sep 18 | 99,013 | 15,834 | 19,447 | 5,832 |
30 Jun 18 | 89,822 | 14,603 | 17,782 | 5,563 |
31 Mar 18 | 86,089 | -3,395 | 16,365 | 5,123 |
31 Dec 17 | 73,665 | -4,606 | 15,624 | 4,770 |
30 Sep 17 | 72,075 | 533 | 15,914 | 3,440 |
30 Jun 17 | 67,594 | 332 | 15,522 | 3,187 |
31 Mar 17 | 66,193 | -626 | 14,984 | 2,633 |
31 Dec 16 | 68,968 | 1,589 | 14,277 | 2,811 |
30 Sep 16 | 64,782 | 1,630 | 12,899 | 3,109 |
30 Jun 16 | 57,417 | 2,098 | 11,714 | 2,504 |
31 Mar 16 | 46,354 | 3,248 | 9,343 | 2,476 |
31 Dec 15 | 32,457 | 2,066 | 6,305 | 2,288 |
30 Sep 15 | 24,263 | 4,816 | 4,267 | 1,679 |
30 Jun 15 | 26,619 | 6,774 | 3,272 | 1,679 |
31 Mar 15 | 27,072 | 6,846 | 3,218 | 1,476 |
31 Dec 14 | 27,332 | 7,563 | 3,082 | 1,045 |
30 Sep 14 | 24,208 | 6,327 | 2,672 | 965 |
30 Jun 14 | 22,184 | 5,412 | 2,128 | 1,131 |
31 Mar 14 | 23,496 | 7,019 | 1,850 | 1,130 |
31 Dec 13 | 23,181 | 7,575 | 2,134 | 822 |
Quality Earnings: A092040 is currently unprofitable.
Growing Profit Margin: A092040 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A092040 is unprofitable, and losses have increased over the past 5 years at a rate of 49.7% per year.
Accelerating Growth: Unable to compare A092040's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A092040 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A092040 has a negative Return on Equity (-9.42%), as it is currently unprofitable.